[Comment] Second-line CAR T cells for lymphomas

Anti-CD19 chimeric antigen receptor (CAR) T cells have shown huge therapeutical potential in the treatment of aggressive B-cell lymphomas beyond second-line of therapy.1–3 But the use of such therapies as a second-line of therapy is a current matter of debate. At the 2021 American Society of Hematology meeting, results of the three randomised clinical trials addressing this question were presented. The ZUMA7,4 BELINDA,5 and the TRANSFORM6 trials included only patients with aggressive B-cell lymphomas with primary refractory disease or with relapse within 12 months of completion of first-line therapy.